Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Strategy

The American College of Rheumatology recommends starting methotrexate monotherapy immediately upon diagnosis of RA in DMARD-naive patients with moderate-to-high disease activity, due to its superior efficacy in slowing radiographic progression and favorable safety profile 1
For patients with low disease activity, hydroxychloroquine is conditionally recommended as first-line therapy, while sulfasalazine is conditionally recommended over methotrexate 1
For patients with moderate-to-high disease activity without poor prognostic factors, methotrexate monotherapy is strongly recommended over hydroxychloroquine, sulfasalazine, leflunomide, or biologic/targeted synthetic DMARD monotherapy 1

For patients with moderate-to-high disease activity and poor prognostic factors, adding a biologic DMARD (TNF inhibitor, IL-6 inhibitor, abatacept, or rituximab) or targeted synthetic DMARD (JAK inhibitor) to methotrexate is recommended 1, 3
In early RA (<6 months duration) with high disease activity and poor prognostic features, anti-TNF biologic with or without methotrexate is recommended 4, 5

If methotrexate is contraindicated or not tolerated, leflunomide or sulfasalazine should be considered as first-line alternatives, which can be used as monotherapy or in combination strategies 1, 3, 6

Short-term glucocorticoids (<3 months) can be conditionally added to conventional synthetic DMARDs as bridging therapy, but longer-term use (≥3 months) is strongly recommended against due to cumulative toxicity 1
Low-dose glucocorticoids (≤10 mg/day prednisone equivalent) should be tapered as rapidly as clinically feasible, ideally within 6 months 6, 3

Disease activity must be monitored every 1-3 months during active disease using validated measures (DAS28, SDAI, or CDAI) 1, 3
At 3 months, therapy must be adjusted if no improvement is seen, and at 6 months, therapy must be adjusted if treatment target (remission or low disease activity) has not been reached 1, 3

If inadequate response to methotrexate monotherapy at 3 months, add another conventional synthetic DMARD to methotrexate or switch to a different conventional synthetic DMARD, or add a biologic DMARD or targeted synthetic DMARD to methotrexate 4, 5, 1, 3
If first biologic or targeted synthetic DMARD fails, switch to another biologic DMARD or targeted synthetic DMARD 3

The treatment goal is sustained remission or low disease activity in every patient, using a treat-to-target approach involving systematic monitoring of disease activity and modification of treatment to minimize disease activity 1, 3

Tapering should only be considered after achieving persistent remission or low disease activity for at least 6 months, starting with glucocorticoids, then biologic or targeted synthetic DMARDs, and finally conventional synthetic DMARDs 1, 3, 6

Avoid delaying DMARD initiation, inadequate methotrexate dosing, prolonged glucocorticoid use, insufficient monitoring frequency, waiting too long to escalate, and premature tapering 6, 1, 3
Screen for tuberculosis before initiating biologic therapy, and assess hepatitis B/C status and cardiovascular, renal, and gastrointestinal risks before treatment selection 4, 5